Placenta research reveals potential for managing chronic inflammation

Research published in the Journal of Extracellular Vesicles suggests that extracellular vesicles (EVs) released by placenta-derived cells may offer new ways to manage chronic inflammation. A study using a stable human trophoblast model found that placenta-derived EVs (PEVs) can reprogram monocytes—key drivers of inflammation—toward an immunomodulatory state that promotes tissue repair and homeostasis rather than simple suppression.

This effect was also observed in monocytes from patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic disorder involving severe tissue damage. The study highlights the potential of using a stable trophoblast model as a reproducible, off-the-shelf source for these immunomodulatory EVs.

Separately, medical information regarding placental health emphasizes the organ's critical role in delivering oxygen and nutrients to a developing baby. Abnormalities such as placenta previa, where the placenta attaches low in the uterus and covers the cervix, can impact delivery plans and require careful medical monitoring to ensure the health of both mother and child.